Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in BRAF or NRAS Mutated Melanoma
NCT00866177Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2009
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in melanoma, sponsored by National Cancer Institute. Primary endpoint: Anti-tumor Response at 4 weeks. Started Mar 2009; status: completed.
02
Drugs
selumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00866177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866177.